Clinical trials: Secondary Malignant Neoplasm of Bone
Bone Metastases
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
A study to evaluate the safety and initial effectiveness of the ExAblate 2100 Conformal Bone System in the treatment of pain resulting from metastatic bone tumors.
- Trial name
- NCT00981578
- Testing
- ExAblate 2100
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- InSightec
Pain in Bone Metastases
A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of VC004 Capsules for Pain in Bone Metastases
This is a randomized, double-blind, placebo-controlled Phase Ib study evaluating the safety and efficacy of VC004 capsules for the relief of moderate-to-severe pain associated with bone metastases
- Trial name
- NCT07731685
- Testing
- VC004 low dose, VC004 high dose
- Where
- 2 sites in China
- Volunteers
- 26 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Breast Cancer, Bone Metastases
BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease
The purpose of the study is to investigate if multiple (up to four) intravenous injections of Xofigo (Alpharadin) have any clinically relevant effect on bone markers in breast cancer patients with bone dominant disease who have…
- Trial name
- NCT01070485
- Testing
- Radium-223 chloride (BAY88-8223)
- Where
- 4 sites in Belgium, Norway and 1 more
- Volunteers
- 23 people
- Sponsor
- Bayer
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00104650
- Testing
- AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
- Volunteers
- 111 people
- Sponsor
- Amgen
Malignant Neoplasm of Prostate
Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease
The purpose of this study is to look at whether F-18 Fluciclovine (i.e. Axumin) is better or as good as F-18 Sodium Fluoride (F-18 NaF) when looking at bone disease from prostate cancer.
- Trial name
- NCT04765423
- Testing
- [F-18] NaF PET/CT, [F-18] fluciclovine PET/CT
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
This phase II trial studies how well reduced intensity donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01384513
- Testing
- Fludarabine, Busulfan, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
This randomized pilot trial studies vaccine therapy and pembrolizumab in treating patients with prostate cancer that does not respond to treatment with hormones (hormone-resistant) and has spread to other places in the body…
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Carcinoma
- Trial name
- NCT02499835
- Testing
- Pembrolizumab, pTVG-HP Plasmid DNA Vaccine
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Wisconsin, Madison
Coronavirus Infection, Orthopedic Disorder
Retrospective Case Series of COVID19+ Patients Undergoing Orthopedic Surgery
Over the last months, the Rizzoli Orthopedic Institute in Bologna, Italy, has drained orthopedic urgencies from all other hospitals in the urban and suburban area.
- Conditions
- Coronavirus Infection, Orthopedic Disorder, Bone Fracture, Bone Metastases
- Trial name
- COVID19&SURG (NCT05881343)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Istituto Ortopedico Rizzoli
Breast Cancer With Bone Metastasis
Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions
Zoledronic acid selectively binds to bone and protects it from being metastasized by tumor cells. This study evaluates the safety and efficacy of zoledronic acid when added to standard therapies in breast cancer patients with…
- Trial name
- NCT00372710
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Novartis
Castration-resistant Prostate Cancer, Bone Metastases
The Combination Therapy With Ra-223 and Enzalutamide
This study is to evaluate preliminary efficacy of Ra-223 in combination with Enzalutamide in progressive CRPC patients with bone metastasis
- Trial name
- CORE-OCU (NCT03305224)
- Testing
- Ra-223 in combination with enzalutamide
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Taro Iguchi, MD, PHD
Breast Cancer
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
Clinical trial in breast cancer patients with bone metastases pretreated for approximately 1 year with a standard zoledronic acid regimen.
- Trial name
- NCT00320710
- Testing
- Zoledronic acid
- Where
- 92 sites in United States
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Bone Neoplasms
Bonefos and the Consumption of Analgesics
The effect of Bonefos on consumption of analgesics (drugs used for pain treatment) in patients with proven bone metastases.
- Trial name
- BICAM (NCT00909142)
- Testing
- Bonefos (Clodronate, BAY94-8393)
- Where
- Czechia
- Volunteers
- 149 people
- Sponsor
- Bayer
Cancer
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation.
- Trial name
- NCT00089141
- Testing
- mycophenolate mofetil
- Where
- 16 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Martin, Paul
Multi-metastatic Cancer
Bipolar RFA of Painful Extra-spinal Bone Metastases
To evaluate the worst pain of cancer patients with painful extra-spinal bone metastases 1 month after bipolar radiofrequency ablation (RFA) performed with the Osteocool system.
- Trial name
- PERFACOOL (NCT03738670)
- Testing
- Percutaneous RFA
- Where
- France
- Volunteers
- 12 people
- Sponsor
- University Hospital, Strasbourg, France
Metastatic Prostate Cancer
ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer
This phase I trial is studying the side effects and best dose of docetaxel when given with zoledronic acid in patients with bone metastasis from prostate cancer that has not responded to hormone therapy.
- Trial name
- ZANTE (NCT00415779)
- Testing
- docetaxel, zoledronic acid
- Where
- 2 sites in Italy
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute, Naples
Castrate-resistant Prostate Cancer
Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer
This is a multi-national, multi-center, open-label, single-arm extension study for the prolongation of bone metastasis-free survival in men with hormone-refractory (androgen independent) prostate cancer.
- Trial name
- NCT01824342
- Testing
- Denosumab
- Where
- 9 sites in Czechia, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Amgen